Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
Newave Pharmaceutical Inc
CellCentric Ltd.
Incyte Corporation
American Regent, Inc.
Sumitomo Pharma America, Inc.
IGM Biosciences, Inc.
Pfizer
Celgene
Prelude Therapeutics
Novo Nordisk A/S
Amgen
Pfizer
Celgene
Celgene
Celgene
Celgene
AbbVie
Calithera Biosciences, Inc
Celgene
Mirati Therapeutics Inc.
Millennium Pharmaceuticals, Inc.